Currently, an ongoing clinical trial is expanding its indication to pediatric plaque psoriasis ( NCT05172726 ), and two Phase III ADORING trials ( NCT05014568 , NCT05032859 ) have demonstrated that 1% Tapinarof cream exhibits highly significant efficacy as well as favorable safety and tolerability in diverse AD patient populations aged 2 years and older (Silverberg, Eichenfield, et al. 2024 ). 4.7.
← all excerpts
T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets.
1
—
—